Clarity Pharmaceuticals Reports $153 Million Cash Balance as Prostate Cancer Trials Advance
CU6: $1.57 -5.99% · MC: $619M
Clarity Pharmaceuticals ended September with approximately $153 million in cash. Its SECuRE treatment trial reached its main expansion-group recruitment target in October, while recruitment continues for a group receiving the treatment alongside enzalutamide. Earlier this week, Clarity reported that its Phase III CLARIFY imaging trial had dosed its target number of participants; results from that trial and AMPLIFY are expected in the first half of next year.

Comments